Skip to main content
GIPResearch.com · Patent and Technology Research

Actelion Pharmaceuticals Ltd. Received a Patent for Benzimidazole Compounds

Actelion Pharmaceuticals Ltd., is a biopharmaceutical company.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Actelion Pharmaceuticals Ltd. Received a Patent for Benzimidazole Compounds
Research and original publication material

Actelion Pharmaceuticals Ltd. Received a Patent for Benzimidazole Compounds — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Actelion Pharmaceuticals Ltd., is a biopharmaceutical company. The Company develops medicines for the treatment of pulmonary arterial hypertension. Actelion Pharmaceuticals Ltd. filed patent application numbered 7448/CHENP/2010 that is titled BENZIMIDAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS. This patent application has been granted as Patent Number 291092. The invention covers Chemical compounds. The invention relates to compounds of formula (I) wherein R1 represents aryl, which is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1- 4)alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl; R2 represents hydrogen, or -CO-R21; R 21 represents (C1-5)alkyl, (C1-3)fluoroalkyl, or (C3-6)cycloalkyl; m represents the integer 2, or 3; p represents the integer 2 or 3; and R3 represents hydrogen or (C1-5)alkyl; and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims  Claim(s) 1-9 are statutorily non-patentable. It relates to the mere discovery of new derivatives and new use for a known substance ie BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS.  As a response to objection, the claims were amended to bring improved efficacy.  Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to Actelion Pharmaceuticals Ltd. Received a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-26. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights